Who invested in Impel NeuroPharma?
Impel NeuroPharma's investors include Alliance of Angels, 5AM Ventures, venBio Partners, Vivo Capital and KKR, and 2 more on record.
United States · Series D startup
7 rounds we have observed, with the 7 investors named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.
Get an email when Impel NeuroPharma raises a new round.Sign up free
Funding summaryUpdated 27 Oct 2026
$107Mraised across 7 rounds since 2010, from 7 sources
Each circle is a round, placed by date and sized by amount. The line above is the running total.
Reported by FinSMEs
Reported by FinSMEsSEC filing: $22M sold, first sale Nov 2016
From a historical funding recordSEC filing: $4.0M sold, first sale Sept 2015
Reported by sec.govSEC filing: $2.6M sold, first sale Nov 2013
Reported by nwinnovation.comSEC filing: $527K sold, first sale Sept 2011
No investor was named in the report.
Reported by sec.govSEC filing: $305K sold, first sale Jan 2010
From the SEC filings it signed: 3 on the team.
On the board, as filediAaron D. RoystonAli D. SatvatDavid D. AllisonDiane D. WilfongMahendra D. ShahRobert D. MittendorffStewart D. ParkerTim D. Nelson
The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.
Impel NeuroPharma's investors include Alliance of Angels, 5AM Ventures, venBio Partners, Vivo Capital and KKR, and 2 more on record.
Impel NeuroPharma has raised $107M across 7 rounds since 2010. One round did not disclose an amount, so the total is a floor.
Impel NeuroPharma's most recent round was a Series D of $68M in Dec 2018.
Its most recent round, $68M in Dec 2018, is also its largest on record.
Impel NeuroPharma's first round on record, in Oct 2011, was backed by Alliance of Angels.
Impel NeuroPharma's latest named round is a Series D, in Dec 2018.
Impel NeuroPharma is based in the United States.
Search every investor by what they have actually funded, then narrow to your stage and market. Free.